Founded in 2017 and headquartered in Northcote, Victoria, ReNerve Limited (ASX: RNV) focuses on creating unique nerve repair materials to address unmet needs in large nerve gap replacements. The company has established laboratories in Melbourne and collaborates with researchers in Australia's premier biomaterials precincts at the CSIRO and Monash University. By engaging in cutting-edge technologies and partnerships, ReNerve aims to develop products that improve the lives of patients requiring nerve repair and regeneration.
ReNerve Limited (ASX:RNV)
Innovating nerve repair. Improving patient outcomes.
About Us
ReNerve Limited is an Australian based medical device company focused on developing and marketing products to enhance patient outcomes and procedures for invasive nerve surgery. ReNerve was established to develop a portfolio of ‘ready-to-use’ products for neuro - and plastic surgeons to produce better patient outcomes in the repair and replacement of peripheral nerves.
Company Overview
Board & Management
Stephen Cooper
Chairman
Stephen was previously Managing Director at Grant Samuel, a leading Australian investment bank.
Stephen has over twenty-five years of experience in Investment Banking and has been responsible for numerous corporate advisory assignments including public company takeovers, mergers, business sales and acquisitions, schemes of arrangement, capital raisings and business valuations.
Stephen has previously served as Chairman of Avexa, an ASX-listed biotechnology company.
Dr Julian Chick
CEO & Managing Director
Dr Julian Chick is an experienced healthcare executive with over 20 years’ experience in senior management including in ASX listed companies Avexa and Admedus, and is currently Non-Executive Director at LTR Pharma (ASX:LTP).
Julian’s previous roles include Chief Executive Officer, COO and Head of Business Development, as well as running early and late-stage R&D projects and launching medical devices into the global markets.
Julian has been involved in developing and obtaining FDA USA clearance for four tissue based medical devices. Julian, while COO at Admedus Ltd was involved in the R&D development, regulatory approval and launch of several tissue products in North America, Europe and Asia.
Julian has eight years’ investment banker experience focused on healthcare and biotechnology. Julian has a PhD in Muscle Physiology.
Dr Michael Panaccio
Non-Executive Director
Dr Michael Panaccio is one of the founders of Starfish Ventures, a venture capital firm that invests in early-stage technology companies and plays an active role in the management of its portfolio.
Michael has been a director of numerous technology businesses in Australia and the USA including SIRTeX Medical Ltd, Engana Pty Ltd (now part of Finisar Corporation), Energy Response (sold to EnerNoc Inc), ImpediMed Ltd, and Protagonist Therapeutics Inc.
Michael currently serves on the boards of Armaron Bio Ltd and Cylite Pty Ltd and ASX listed dorsaVi Ltd (ASX:DVL).
Dr David Rhodes
Executive Director & CSO
Dr David Rhodes has more than 20 years’ experience in healthcare and biotechnology industries, where he has held numerous senior management roles and developed technologies through to market approval.
David has been involved in obtaining several FDA USA and European marketing authorisation approvals for medical devices. Previous roles include senior researcher at Amrad, Chief Scientific Officer of the medical devices company Admedus Ltd, COO of AdAlta Ltd and senior executive and Head of Drug Discovery and Senior Vice President Biology at Avexa Ltd.
David has successfully led multiple technology development programs attracting significant levels of funding from many State and Federal Government initiatives and research institute programs.
David has a PhD in Biochemistry.
Dr Alex Adamides
Chief Medical Officer
Dr Alex Adamides studied medicine at the University of Nottingham, UK, and completed his basic surgical training in Edinburgh before undertaking his neurosurgical training in Australia.
Dr Adamides became a fellow of the Royal Australasian College of Surgeons in 2012 and has since been a consultant neurosurgeon at the Royal Melbourne Hospital.
Dr Adamides is an honorary clinical senior lecturer at Melbourne University and a reviewer for the Journal of Clinical Neuroscience.
Working with ReNerve, Dr Adamides has developed pre-clinical models testing the safety and efficacy of surgical implants for the repair of peripheral nerves and dura.
